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httpCarotid-subclavian bypass and subclavian-carotid
transposition in the thoracic endovascular aortic
repair era
Arin L. Madenci, MPH,a C. Keith Ozaki, MD,b Michael Belkin, MD,b and James T. McPhee, MD,c
Ann Arbor, Mich; and Boston, Mass
Objective: Beyond traditional indications, subclavian revascularization is increasingly performed to allow for aortic arch
debranching in the setting of thoracic endovascular aortic repair (TEVAR). Endovascular treatment options for
subclavian disease have emerged, perhaps altering the patient population undergoing open revascularization. We lever-
aged prospectively collected American College of Surgeons (ACS)-National Surgical Quality Improvement Program
(NSQIP) data to delineate evolving stroke and mortality rates after carotid-subclavian bypass (CSB) and subclavian-
carotid transposition (SCT) in this dynamic context.
Methods: The ACS-NSQIP database (2005 to 2010) was used to examine patients who underwent CSB or SCT. Patients
admitted for emergency cases were excluded. Factors associated with 30-day postoperative cerebrovascular accident
(CVA) or death (CVA/D) were deﬁned using univariable and multivariable analyses.
Results: CSB comprised 41% of revascularizations associated with TEVAR and 89% of isolated revascularizations.
A greater proportion of TEVARs were performed in the SCT group (37.4% vs 4.9%; P < .01). The groups were similar in
demographic characteristics and prevalence of comorbidities. Overall stroke, mortality, and combined CVA/D rates were
3.5% (n[ 31), 3.3% (n[ 29), and 5.8% (n[ 51), respectively. Surgical approach did not affect outcome. The CVA/D
rate was 10.2% (n[ 9) for revascularization in conjunction with TEVAR and 5.3% (n[ 42) for isolated reconstruction
(P [ .06). For patients undergoing isolated revascularization, increasing age (adjusted odds ratio, 1.06; 95% conﬁdence
interval, 1.03–1.10; P < .01), and nonindependent functional status (odds ratio, 3.49; 95% conﬁdence interval,
1.41-8.68; P < .01) were signiﬁcantly associated with CVA/D.
Conclusions: In this contemporary data set, there was no signiﬁcant difference in CVA/D by surgical approach. TEVAR
trended toward an association with CVA/D compared with isolated subclavian reconstruction. CVA/D continues to
complicate contemporary CSB and SCT, especially among elderly and nonindependent patient subsets. (J Vasc Surg
2013;57:1275-82.)Although upper extremity occlusive disease comprises TEVARs,5 and a recent large safety trial mandated routine
only 5% of all limb ischemia, the morbidity can be high
due to its effect on hand and arm function.1 In addition,
the surgical approaches to upper extremity revasculariza-
tion are complicated by the attendant risk of neurologic
complications. Beyond traditional indications for occlusive
disease, subclavian revascularization is increasingly per-
formed to allow for aortic arch debranching in the setting
of thoracic endovascular aortic repair (TEVAR).2-4 Left
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Subclavian revascularization options include direct open
reconstruction, cervical reconstruction, and percutaneous
techniques. Owing to their lower risk of major morbidity
and death,9 percutaneous techniques have partly replaced
direct open repairs and cervical reconstructions.10 There
remain instances in which the endovascular approach to
revascularization is not indicated, is technically unfeasible,
or has previously failed, making open surgical approaches of
carotid-subclavian bypass (CSB) or subclavian-carotid trans-
position (SCT) necessary for these now selected patients.
In this dynamic context, it is unclear how contempo-
rary stroke and mortality rates vary among the extrathora-
cic reconstructive techniques. Prior reports are dated, span
decades, or are limited to single-institutional reports with
small comparison groups.11-14 The purpose of this study
was to deﬁne the respective associations of CSB and
SCT, in terms of overall stroke and mortality rates for
TEVAR and non-TEVAR patients, from a contemporary
multicenter data set.
METHODS
Data source. This was an analysis of prospectively
collected, peer-controlled, validated data from the American1275
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Improvement Program (NSQIP) database, years 2005 to
2010. As of the most recent of its annual installments (2010),
NSQIP collects 210 variables fromw360,000 surgical cases
at 258 institutions across the United States. The data consist
of preoperative risk factors, intraoperative factors, and post-
operative outcomes.NSQIPdata is sampled fromall inpatient
or outpatient operations requiring general anesthesia, spinal
anesthesia, and epidural anesthesia, excluding trauma and
transplant surgeries.15
Adult patients who underwent CSB or SCT were
included in this study and selected using Current Proce-
dural Terminology (CPT, American Medical Association,
Chicago, Ill) codes (Supplementary Table, online only).
Patients who were admitted for emergency surgery (eg,
aortic rupture; based on NSQIP variable “Emergency
Case”) were excluded from the study. TEVAR and carotid
endarterectomy performed during the same hospital stay
were also identiﬁed using CPT codes.
In addition to demographic variables, clinical factors
analyzed included recent myocardial infarction (MI),
congestive heart failure, hypertension, chronic obstructive
pulmonary disorder (COPD), diabetes mellitus, dialysis-
dependence, and smoking status. The American Society
of Anesthesiologists (ASA) classiﬁcation, a preoperative
anesthesiology assessment ranging from 1 (least severe
physical status) to 6 (most severe physical status),16 was
used as a proxy for preoperative status. Functional health
status before surgery was dichotomized into independent
vs nonindependent (ie, partially or totally dependent) func-
tional status, due to a limited number of patients in the
“totally dependent” category. The effect of hospital
volume on outcome could not be assessed due to the
NSQIP sampling strategy.
End points. The primary outcome measure was
a composite of 30-day postoperative cerebrovascular acci-
dent (CVA) or death (CVA/D), deﬁned by the NSQIP
variables “Stroke/Cerebral Vascular Accident (CVA),” as
“an embolic, thrombotic, or hemorrhagic vascular accident
or stroke with motor, sensory, or cognitive dysfunction (for
example, hemiplegia, hemiparesis, aphasia, sensory deﬁcit,
impaired memory) that persists for 24 or more hours” and
value of the NSQIP variable “Days from Operation to
Death” #30 days. Secondary outcomes included post-
operative length of stay, wound infection (superﬁcial, deep,
or organ space), pneumonia, reintubation, pulmonary
embolism, acute renal failure, and MI.
Statistical analysis. Univariable analyses were per-
formed to compare surgical approaches and to assess
factors associated with study outcomes. The Kruskal-
Wallis test was used for continuous variables. The c2 test
or the Fisher exact test was used for categoric variables,
where appropriate. We then constructed a multivariable
logistic regression model for the primary outcome. The
stepwise elimination method was used, including the vari-
ables of sex, race, age, TEVAR, smoking status, diabetes,
hypertension, history of CVA, history of MI, COPD,
history of congestive heart failure, preoperative dialysisrequirement, functional status, ASA classiﬁcation, and
preoperative laboratory values. LSA coverage was also
included in the model among TEVAR patients.
An interaction term was included to assess whether the
effect of surgical approach (CSB vs SCT) was modiﬁed by
TEVAR. Regardless of the signiﬁcance of interaction
between surgical approach (CSB vs SCT) and TEVAR (vs
non-TEVAR), we separately addressed patients who did
and did not undergo TEVAR. This stratiﬁcation controlled
for TEVAR, a known risk factor for perioperative stroke,6
and also permitted us to obtain meaningful estimates of
30-day CVA/D in the face of possible effect measure modi-
ﬁcation by TEVAR. Owing to likely underlying differences
between populations, the goal of stratiﬁcation was not,
however, to compare theTEVARandnon-TEVARpatients.
A value of P < .50 was required to enter the model and
a P < .30 was required to remain in the ﬁnal model.
Regardless of univariable association, surgical approach
was forced into all multivariable models as the primary
exposure variable of interest. Patients with missing data
were excluded from each respective univariable and multi-
variable analysis. Assessment of temporal trend was con-
ducted using the Cochran-Armitage test for trend. Given
prior estimates of CVA/D with subclavian revasculariza-
tion of 5%, in order to detect odds ratios of 1.5 and 2.0,
1237 and 382 patients per group would be required to
attain 80% power, respectively. A P < .05 was considered
statistically signiﬁcant. All data were analyzed using SAS
9.3 software (SAS Institute, Cary, NC).
RESULTS
Overall results. Of 918 adults who underwent CSB or
SCT, 41 were excluded as emergency cases. An overview of
baseline patient demographic and clinical data from the
877 study participants is reported in Table I. There were
738 patients who underwent CSB (84.2%) and 139 who
underwent SCT (15.8%). Patients were predominantly
Caucasian (83.1%) and aged w65 years. The most
common comorbidity was hypertension (79.0%).
TEVAR was performed in 10.0% of patients and
carotid endarterectomy in 4.2%. A smaller proportion of
TEVARs were performed in the CSB (4.9%) than in the
SCT (37.4%) group (P < .01). The SCT cohort had lower
median preoperative blood urea nitrogen (BUN) level
(CSB, 17.0 vs SCT, 16.0 mg/dL; P ¼ .02) and creatinine
level (CSB, 1.0 vs SCT, 0.9 mg/dL; P ¼ .04). The groups
were otherwise similar with regard to baseline demo-
graphics and comorbidities.
Overall, 51 patients (5.8%) met the end point of
CVA/D. The CVA/D rate was 5.6% in the CSB group
and 7.2% in the SCT group (P ¼ .45). CVA occurred in
31 patients (3.5%). The stroke rate was 3.4% in the CSB
group and 4.3% in the SCT group (P ¼ .61). The overall
mortality rate was 3.3%. The mortality rate was 3.1% In the
CSB group compared with 4.3% in the SCT group, with
no signiﬁcant difference on unadjusted analysis (P ¼ .44).
In the overall cohort, there was no signiﬁcant difference
betweenCSB and SCT in secondary postoperative outcomes
Table I. Baseline characteristics of the entire cohort, carotid-subclavian bypass (CSB) group, and subclavian-carotid
transposition (SCT) group
Variablea Overall (n ¼ 877) CSB (n ¼ 738) SCT (n ¼ 139) P
Female gender 447 (51.1) 370 (50.3) 77 (55.4) .27
Caucasian race 719 (83.1) 611 (83.8) 108 (79.4) .21
Age, years 66.0 (57.0-74.0) 66.0 (57.0-74.0) 66.0 (52.0-76.0) .67
TEVAR 88 (10.0) 36 (4.9) 52 (37.4) <.01b
Carotid endarterectomy 37 (4.2) 33 (4.5) 4 (2.9) .39
Comorbidities
Current smoker 360 (41.1) 301 (40.8) 59 (42.5) .71
Diabetes 145 (16.5) 128 (17.3) 17 (12.2) .14
History of
Hypertension 693 (79.0) 582 (78.9) 111 (79.9) .79
CVA 162 (18.5) 143 (19.4) 19 (13.7) .11
Myocardial infarction 17 (1.9) 16 (2.2) 1 (0.7) .50
COPD 145 (16.5) 123 (16.7) 22 (15.8) .81
Congestive heart failure 19 (2.2) 18 (2.4) 1 (0.7) .34
Dialysis dependent 12 (1.4) 12 (1.6) 0 (0.0) .23
Functional status .69
Independent 818 (93.3) 688 (93.2) 130 (93.5)
Partially dependent 46 (5.3) 38 (5.1) 8 (5.8)
Totally dependent 13 (1.5) 12 (1.6) 1 (0.7)
ASA classiﬁcation .14
No disturbance (1) 6 (0.7) 5 (0.7) 1 (0.7)
Mild disturbance (2) 81 (9.2) 61 (8.3) 20 (14.4)
Severe disturbance (3) 595 (67.8) 504 (68.3) 91 (65.5)
Life-threatening (4) 195 (22.2) 168 (22.8) 27 (19.4)
Pre-op lab values
Sodium, mmol/L 139.0 (137.0-141.0) 139.0 (137.0-141.0) 140.0 (137.0-141.0) .81
BUN, mg/dL 17.0 (12.0-22.0) 17.0 (12.0-22.0) 16.0 (11.0-20.0) .02b
Creatinine, mg/dL 1.0 (0.8-1.3) 1.0 (0.8-1.3) 0.9 (0.8-1.2) .04b
BUN/creatinine 16.7 (12.5-20.8) 16.7 (12.7-20.9) 16.0 (11.7-19.3) .12
Albumin, g/dL 3.9 (3.5-4.2) 3.9 (3.5-4.3) 3.9 (3.5-4.2) .94
Total bilirubin, mg/dL 0.5 (0.3-0.7) 0.5 (0.3-0.7) 0.6 (0.3-0.7) .48
SGOT, mg/dL 21.0 (17.0-27.0) 22.0 (17.0-27.0) 21.0 (17.0-26.0) .56
Alkaline phosphatase, IU/L 79.0 (64.0-99.0) 79.0 (65.0-99.0) 78.0 (60.0-99.0) .35
WBC, 106/mL 7.5 (6.2-9.2) 7.5 (6.2-9.1) 7.9 (6.4-9.7) .17
Hematocrit, % 39.1 (35.4-41. 9) 39.1 (35.3-42.0) 39.2 (35.9-41.5) .85
Platelets, 109/L 230.0 (185.0-283.0) 230.0 (183.0-282.5) 228.5 (197.0-283.0) .75
PTT, sec 29.0 (26.5-32.4) 29.0 (26.5-32.5) 28.8 (26.5-32.0) .63
INR 1.0 (1.0-1.1) 1.0 (1.0-1.1) 1.0 (1.0-1.1) .25
Outcomes
Length of stay, days 2.5 (1.0-6.0) 2.0 (1.0-6.0) 3.0 (2.0-7.0) .27
CVA 31 (3.5) 25 (3.4) 6 (4.3) .61
Death 29 (3.3) 23 (3.1) 6 (4.3) .44
CVA/death 51 (5.8) 41 (5.6) 10 (7.2) .45
ASA, American Society of Anesthesiologists Physical Status Classiﬁcation; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic
obstructive pulmonary disease; CVA, cerebrovascular accident; INR, international normalized ratio; PTT, partial thromboplastin time; SGOT, serum glutamic
oxaloacetic transaminase; TEVAR, thoracic endovascular aortic repair; WBC, white blood cells.
aCategoric data are reported as number (%) and continuous data as median (interquartile range).
bP < .05.
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bation (P ¼ .24), pulmonary embolism (P ¼ .99), acute
renal failure (P ¼ .99), and MI (P ¼ .99).
In the multivariable regression model, female gender
(adjusted odds ratio [OR], 3.20; 95% conﬁdence interval
[CI], 1.04-9.83; P ¼ .04), age (OR per 10 years, 2.21;
95% CI, 1.28-3.81; P < .01), nonindependent functional
status (OR, 6.83; 95% CI, 1.97-23.66; P < .01), and
BUN (OR per 1-U change, 1.05; 95% CI, 1.01-1.09;
P < .01) were signiﬁcantly associated with CVA/D
(Table II). The interaction term between surgical approach
and TEVAR was signiﬁcant (P ¼ .04), indicating effectmeasure modiﬁcation by TEVAR. Surgical approach
(SCT vs CSB) was not signiﬁcantly associated with
CVA/D (OR, 0.74; 95% CI, 0.17-3.09; P ¼ .67).
Because the interaction term between surgical approach
and TEVAR was signiﬁcant and to provide more clinically
meaningful estimates, we stratiﬁed the study outcomes by
the presence or absence of TEVAR and surgical approach
to subclavian revascularization (Table III). On crude anal-
ysis, TEVAR was not signiﬁcantly associated with CVA
(P ¼ .23) but approached signiﬁcance for CVA/D (P ¼
.06) and death (P ¼ .06). Crude CVA/D rates were not
signiﬁcantly different between CSB and SCTwhen stratiﬁed
Table III. Outcome, stratiﬁed by thoracic endovascular
aortic repair (TEVAR) and surgical approach
Variable No.
CVA/D,
No. (%)
Death,
No. (%)
CVA,
No. (%)
All patients 877 51 (5.8) 29 (3.3) 31 (3.5)
TEVAR
Overall 88 9 (10.2) 6 (6.8) 5 (5.7)
CSB 36 5 (13.9) 3 (8.3) 3 (8.3)
SCT 52 4 (7.7) 3 (5.8) 2 (3.9)
LSA coverage
Yes 40 8 (20.0)a 6 (15.0)a 4 (10.0)
No 48 1 (2.1) 0 (0.0) 1 (2.1)
Non-TEVAR
Overall 789 42 (5.3) 23 (2.9) 26 (3.3)
CSB 702 36 (5.1) 20 (2.9) 22 (3.1)
SCT 87 6 (6.9) 3 (3.5) 4 (4.6)
CSB, Carotid-subclavian bypass; CVA, cerebrovascular accident; CVA/D,
cerebrovascular accident or death; LSA, left subclavian artery; SCT,
subclavian-carotid transposition.
aP < .01.
Table II. Multivariable stepwise selection model for
postoperative cerebrovascular accident (CVA) or death
(CVA/D)
Factor Adjusted OR (95% CI) P
SCT (vs CSB)a 0.74 (0.17-3.09) .67
Female gender 3.20 (1.04-9.83) .04b
Caucasian race 0.39 (0.13-1.19) .10
Age (per 10 years) 2.21 (1.28-3.81) <.01b
Current smoker 2.69 (0.92-7.82) .07
Hypertension 5.43 (0.57-52.19) .14
Nonindependent 6.83 (1.97-23.66) <.01b
Pre-op lab values (per 1 unit)
Sodium 1.16 (0.97-1.39) .11
Blood urea nitrogen 1.05 (1.01-1.09) .01b
Total bilirubin 0.57 (0.29-1.10) .09
CI, Conﬁdence interval; CSB, carotid-subclavian bypass; OR, odds ratio;
SCT, subclavian-carotid transposition.
aSurgical approach (CSB vs SCT) was forced into the model as the variable
of interest.
bP < .05.
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subclavian revascularization between TEVAR and non-
TEVAR patients.
Subclavian revascularization with TEVAR. We
separately addressed the cohort that underwent TEVAR to
obtain meaningful estimates of outcomes with cervical
reconstruction for two potentially heterogenous groups:
TEVAR and non-TEVAR. Baseline characteristics were
similar among patients who underwent CSB compared with
SCT (Table IV). The overall TEVAR CVA/D rate was
10.2%. CVA/D tended to be higher in the CSB group
(13.9%) than the SCT group (7.7%), but the difference was
not statistically signiﬁcant (P ¼ .48). LSA coverage was
associated with CVA/D (P < .01) and death (P < .01;
Table III). Other outcomes are reported in Table IV.
There was no signiﬁcant difference between the two
surgical approaches in the secondary postoperative out-
comes of infection (P ¼ .99), pneumonia (P ¼ .30), rein-
tubation (P ¼ .26), pulmonary embolism (P ¼ .99), acute
renal failure (P ¼ .57), and MI (P ¼ .99). In the stepwise
multivariable model, no factors were signiﬁcantly associated
with CVA/D, including SCT vs CSB surgical approach
(OR, 0.15; 95% CI, 0.01-1.50; P ¼ .11) (Table V).
Isolated subclavian revascularization. For those
undergoing subclavian revascularization alone, the patients
who underwent SCT were younger (mean age, 60.2 vs
64.9 years; P ¼ .01) and had lower mean ASA class (3.1 vs
2.9; P¼ .01) than patients who underwent CSB. On preop-
erative laboratory evaluations, the SCT cohort had lower
preoperative BUN (median CSB, 17.0 mg/dL vs SCT,
16.0 mg/dL; P ¼ .02) and creatinine (median CSB, 1.0
mg/dL vs SCT, 0.9 mg/dL; P¼ .04). Baseline characteris-
tics were otherwise similar between the surgical approaches
(Table VI). The CVA/D rates were similar for patients
undergoing CSB and SCT (5.1% vs 6.9%; P ¼ .45). Other
outcomes are displayed in Table VI. There was no signiﬁcant
difference between the two surgical approaches with regard
to secondary postoperative outcomes of infection (P¼ .99),pneumonia (P ¼ .09), reintubation (P ¼ .15), pulmonary
embolism (P ¼ .50), acute renal failure (P ¼ .99), and MI
(P ¼ .99). In the multivariable analysis, increasing age (OR
per 10 years, 2.32; 95% CI, 1.29-4.17; P < .01), current
smoking status (OR, 3.58; 95% CI, 1.07-11.96; P ¼ .04),
nonindependent functional status (OR, 7.34; 95%CI, 2.10-
25.71; P < .01), and elevated white blood cells (OR
per 1 unit, 1.22; 95% CI, 1.01-1.48; P ¼ .04) were signiﬁ-
cantly associated with CVA/D (Table VII). SCT vs CSB
surgical approach to subclavian revascularization was
not associated with CVA/D (OR, 0.94; 95% CI, 0.15-5.86;
P ¼ .95).
Temporal trends. In the TEVAR cohort, the percent-
ages of revascularizations performed with CSB and SCT
over time from years 2006 to 2010 are displayed in
Supplementary Fig 1 (online only). Of the 2101 non-
emergent TEVAR procedures included in the NSQIP
database, 4.2% underwent subclavian revascularization with
CSB or SCT during the same hospitalization. Overall, CSB
comprised 40.9% of revascularizations in the TEVAR group
(n ¼ 36). During years in which more than one TEVAR-
associated revascularization case was captured (2007 to
2010), the proportion of CSBs (vs SCTs) performed ranged
from 20.0% to 47.6%. The trend over time was not signiﬁ-
cant (P ¼ .96).
Among patients undergoing isolated subclavian revascu-
larization, the percentages of revascularizations with CSB
and SCT over time from years 2006 to 2010 are displayed
in Supplementary Fig 2 (online only). Overall, CSB
comprised 702 of 789 revascularizations (89.0%) in this
non-TEVAR cohort. Between the years 2005 and 2010,
the proportion of CSBs performed for revascularization
remained stable between 81.8% and 90.2%. The trend over
time was not signiﬁcant (P ¼ .50).
DISCUSSION
This comparative effectiveness study represents a
modern, large-scale analysis of postoperative complications
Table IV. Baseline characteristics of the thoracic endovascular aortic cohort, stratiﬁed by carotid-subclavian bypass (CSB)
vs subclavian-carotid transposition (SCT)
Variablea Overall (n ¼88) CSB (n ¼36) SCT (n ¼52) P
Female gender 40 (45.5) 16 (44.4) 24 (46.1) .87
Caucasian race 68 (77.3) 26 (72.2) 42 (80.8) .34
Age, years 71.0 (60.5-79.0) 67.5 (60.5-76.0) 72.0 (60.5-80.0) .19
Carotid endarterectomy 2 (2.3) 1 (2.8) 1 (1.9) >.99
LSA coverage 40 (45.5) 17 (47.2) 23 (44.2) .83
Comorbidities
Current smoker 26 (29.5) 9 (25.0) 17 (32.7) .44
Diabetes 10 (11.4) 5 (13.9) 5 (9.6) .73
History of
Hypertension 80 (90.9) 33 (91.7) 47 (90.4) >.99
CVA 13 (14.8) 7 (19.4) 6 (11.5) .37
Myocardial infarction 0 (0.0) 0 (0.0) 0 (0.0) >.99
COPD 16 (18.2) 5 (13.9) 11 (21.1) .39
Congestive heart failure 0 (0.0) 0 (0.0) 0 (0.0) >.99
Dialysis dependent 0 (0.0) 0 (0.0) 0 (0.0) >.99
Functional status .77
Independent 77 (87.5) 31 (86.1) 46 (88.5)
Partially dependent 8 (9.1) 3 (8.3) 5 (9.6)
Totally dependent 3 (3.4) 2 (5.6) 1 (1.9)
ASA classiﬁcation .27
No disturbance (1) 0 (0.0) 0 (0.0) 0 (0.0)
Mild disturbance (2) 5 (5.7) 1 (2.8) 4 (7.7)
Severe disturbance (3) 50 (56.8) 18 (50.0) 32 (61.5)
Life-threatening (4) 33 (37.5) 17 (47.2) 16 (30.8)
Pre-op lab values
Sodium, mmol/L 139.0 (137.5-141.0) 138.0 (137.0-139.0) 140.0 (138.0-141.0) .11
BUN, mg/dL 17.0 (10.0-23.0) 18.0 (11.0-27.0) 16.5 (10.0-20.0) .17
Creatinine, mg/dL 1.0 (0.8-1.4) 1.2 (0.8-1.5) 1.0 (0.8-1.3) .20
BUN/creatinine 15.3 (11.4-18.0) 15.3 (12.7-20.0) 14.5 (11.1-17.8) .43
Albumin, g/dL 3.6 (3.1-3.9) 3.5 (3.1-3.9) 3.6 (3.1-4.0) .98
Total bilirubin, mg/dL 0.7 (0.5-0.9) 0.7 (0.5-0.9) 0.6 (0.5-0.9) .54
SGOT, mg/dL 22.0 (18.0-30.0) 23.0 (19.5-44.0) 21.0 (17.0-27.0) .12
Alkaline phosphatase, IU/L. 73.0 (57.0-90.0) 65.5 (53.0-90.0) 75.0 (62.0-86.0) .50
WBC, 106/mL 8.0 (6.2-9.7) 7.5 (6.2-9.3) 8.2 (6.0-9.8) .82
Hematocrit, % 38.1 (32.2-41.0) 36.3 (29.6-40.5) 38.3 (34.7-41.4) .07
Platelets, 109/L 224.0 (179.0-267.0) 236.0 (185.0-270.0) 222.0 (174.0-259.0) .49
PTT, sec 29.0 (26.3-33.1) 28.3 (25.4-33.9) 29.1 (26.9-30.9) .67
INR 1.1 (1.0-1.1) 1.1 (1.0-1.1) 1.0 (1.0-1.1) .71
Outcomes
Length of stay, days 6.0 (4.0-13.0) 6.0 (5.0-21.0) 6.0 (3.0-9.0) .21
CVA 5 (5.7) 3 (8.3) 2 (3.9) .39
Death 6 (6.8) 3 (8.3) 3 (5.8) .69
CVA/death 9 (10.2) 5 (13.9) 4 (7.7) .48
ASA, American Society of Anesthesiologists Physical Status Classiﬁcation; BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease; CVA,
cerebrovascular accident; INR, international normalized ratio; PTT, partial thromboplastin time; SGOT, serum glutamic oxaloacetic transaminase;WBC, white
blood cell.
aContinuous data are reported as median (interquartile range) and categoric data as number (%).
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for subclavian revascularization. The overall rate of
CVA/D with subclavian revascularization was 10.2% when
performed in conjunction with TEVAR and 5.3% when
performed as an isolated reconstruction (P¼ .06). No signif-
icant difference between the CSB and SCT groups was
found in crude or adjusted complication rates. In the overall
cohort, advanced age, female gender, nonindependent func-
tional status, and elevated preoperative BUN were associ-
ated with CVA/D.
Recent literature on the use of TEVAR for thoracic aortic
aneurysmal repair showeda concomitant 30-dayCVA/Drateas low as 4.4% in an industry-sponsored trial selected patient
population.6 The study was not designed to assess differences
in outcome between the surgical approaches to subclavian
revascularization. In the current report, reconstruction with
TEVAR with subclavian revascularization had a higher rate
of CVA/D at 10.2%. One possible explanation is that the
aforementioned studyalso includedpatientswith less complex
anatomic disease, and <20% in the total study population
required left LSA revascularization. All TEVAR patients in
the present study also underwent subclavian revasculariza-
tion, and 45% had LSA coverage during TEVAR. Because
we used a national population from the NSQIP database,
Table V. Thoracic endovascular aortic repair (TEVAR)
cohort: Multivariable stepwise selection model for
cerebrovascular accident/death (CVA/D)
Factor Adjusted OR (95% CI) P
SCT (vs CSB)a 0.15 (0.01-1.50) .11
CI, Conﬁdence interval; CSB, carotid-subclavian bypass; OR, odds ratio;
SCT, subclavian-carotid transposition.
aSurgical approach (CSB vs SCT) was forced into the model as the variable
of interest.
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assess difference in CVA/D rate between the surgical
approaches in the context of TEVAR.
Surgical approach was not signiﬁcant in the ﬁnal multi-
variable model for the TEVAR cohort, supporting the
conventional notion that the technique used is at the discre-
tion of the surgeon. No other independent factors were
statistically signiﬁcant. This is possibly due to a colinear
effect of the presence of TEVAR in the model with its atten-
dant risk of neurologic complication and death. Our results
suggest that a portion of the stroke and mortality rate may
be due to the revascularization procedure. Patients who
underwent cervical reconstruction without TEVAR had
a persistent combined CVA/D rate of 5%. Furthermore,
prior studies of cervical reconstruction without TEVAR
have reported CVA/D rates as high as 11%.13
In terms of patients undergoing cervical reconstruction
of the subclavian artery for occlusive disease alone, a wide
range of historical CVA/D rates have been reported,
ranging from <1% to 11.0%.11-14 The overall CVA/D
rate observed in the present study fell within this range at
5.3%. It is possible that this latter rate is a more precise
assessment of the CVA/D rate associated with subclavian
revascularization because many previous studies had
a limited sample size (range, 27-40 patients), which predis-
poses to an uncertainty of estimates.11-13 Takach et al,14 in
their 2011 retrospective institutional study of 287 CSB
patients, reported a stroke rate of 2.1%. Of note, their study
spanned 5 decades (1965-2010),14 during which time
mortality rates have decreased due to advances in surgical
technique, perioperative care, and systems that reduce vari-
ability in care, making it difﬁcult to make a direct compar-
ison with our work.14,17
Although operations for subclavian revascularization are
rare at any single institution, our use of the NSQIP data may
provide improved estimates because of the large sample size,
narrow timeframe of data (2005 to 2010), and consistent
collection of outcomes across the comparison groups. Our
ﬁnal multivariable model for the non-TEVAR cohort
indicated that surgical approach was not associated with
CVA/D. Advanced age, nonindependent functional status,
smoking, and increased preoperative white blood cell count
were each signiﬁcantly associated with CVA/D. Although
concurrent carotid endarterectomy had previously been
found to be a risk factor for postoperative stroke,13 this
was not borne out in the present analysis.In recent years, CSB comprised w40% of subclavian
revascularizations associated with TEVAR and w90% of
isolated subclavian revascularizations. These proportions
appear not to have signiﬁcantly changed since 2005. Simi-
larly, in two small single-institution studies, CSB (as
opposed to SCT) was performed for TEVAR-associated
LSA revascularization 76.5%18 and 44.7%19 of the time.
These studies did not assess the difference in postoperative
complication rates between the surgical approaches.
A likely explanation for the persistently elevated
observed stroke andmortality rates (>5%) for cervical recon-
structions may indirectly relate to the preferential use of
percutaneous endovascular techniques of subclavian revas-
cularization for ﬁrst-line therapy.20 The most invasive
approach to revascularization with the highest risk proﬁle
is direct transthoracic aortic arch reconstruction, which
possesses a 14.7% operative mortality rate.21 Less invasive
extrathoracic approaches include CSB and SCT. More
recently, percutaneous endovascular techniques, including
balloon angioplasty and intraluminal stenting, have become
the ﬁrst-line modalities for proximal subclavian as well as
innominate occlusive disease when feasible.20
The open surgical approaches of CSB and SCTmay have
thus become increasingly reserved for patients with more
severe disease. For example, patients with prior coronary
artery bypass grafting in which the left internal mammary
artery was used often must undergo open subclavian recon-
struction to expand the landing zone for TEVAR. In addi-
tion, patients with renal disease may not be able to
withstand the contrast agent required for percutaneous
transluminal angioplasty or stenting. This possible selection
bias may explain the persistently elevated 30-day CVA/D
rate of 5.3% among patients undergoing isolated subclavian
reconstruction despite temporal reductions in perioperative
morbidity and death in other surgical procedures.
This study was limited by its nonrandomized design
with the inherent risk of confounding and bias. Some
patients may have had history of endovascular supra-aortic
trunk revascularization. We were unable to discern if
TEVAR was performed during the concurrent case or the
same hospital admission or to assess whether patients under-
went TEVAR during a distinct hospitalization from open
reconstruction. This may have caused misclassiﬁcation of
patients into the non-TEVAR cohort. The indication for
upper extremity revascularization could not be adequately
assessed. Finally, perioperative medical adjuncts, such as
aspirin or statin medications, are unknown.
Further, with administrative data, despite the extensive
abstraction process used by the ACS-NSQIP, granular clin-
ical data, such as patient symptoms, carotid clamp times,
shunt use, vessel quality, and prior neck surgery, are not
captured and thus might lead to some information bias in
the analyses. Likewise, patency end points could not be
assessed. However, there is no reason to suspect this to
affect one exposure group more than another and might
ultimately bias toward the null. With regard to the end
point of stroke, this diagnosis was not conﬁrmed by
Table VI. Baseline characteristics of the non-thoracic endovascular aortic repair (TEVAR) cohort stratiﬁed by carotid-
subclavian bypass (CSB) vs subclavian-carotid transposition bypass (SCT)
Variablea Overall (n ¼789) CSB (n ¼ 702) SCT (n ¼ 87) P
Female gender 407 (51.8) 354 (50.6) 53 (60.9) .07
Caucasian race 651 (83.8) 585 (84.4) 66 (78.6) .17
Age, years 66.0 (57.0-74.0) 66.0 (57.0-74.0) 64.0 (52.0-72.0) .01b
Carotid endarterectomy 35 (4.4) 32 (4.6) 3 (3.5) .79
Comorbidities
Current smoker 334 (42.3) 292 (41.6) 42 (48.3) .23
Diabetes 135 (17.1) 123 (17.5) 12 (13.8) .38
History of
Hypertension 613 (77.7) 549 (78.2) 64 (73.6) .33
CVA 149 (18.9) 136 (19.4) 13 (14.9) .32
Myocardial infarction 17 (2.1) 16 (2.3) 1 (1.1) .71
COPD 129 (16.3) 118 (16.8) 11 (12.6) .32
Congestive heart failure 19 (2.4) 18 (2.6) 1 (1.1) .71
Dialysis-dependent 12 (1.5) 12 (1.7) 0 (0.0) .38
Functional status .71
Independent 741 (93.9) 657 (93.4) 84 (96.5)
Partially dependent 38 (4.8) 35 (5.0) 3 (3.5)
Totally dependent 10 (1.3) 10 (1.4) 0 (0.0)
ASA classiﬁcation .01b
No disturbance (1) 6 (0.8) 5 (0.7) 1 (1.1)
Mild disturbance (2) 76 (9.6) 60 (8.5) 16 (18.4)
Severe disturbance (3) 545 (69.1) 486 (69.2) 59 (67.8)
Life-threatening (4) 162 (20.5) 151 (21.5) 11 (12.6)
Pre-op lab values
Sodium, mmol/L 139.0 (137.0-141.0) 139.0 (137.0-141.0) 139.0 (137.0-141.0) .73
BUN, mg/dL 17.0 (12.0-22.0) 17.0 (12.0-22.0) 15.0 (11.0-20.0) .03b
Creatinine, mg/dL 1.0 (0.8-1.2) 1.0 (0.8-1.2) 0.9 (0.8-1.1) <.01b
BUN/creatinine 16.9 (12.7-20.8) 16.9 (12.7-21.0) 17.0 (12.8-20.0) .69
Albumin, g/dL 3.9 (3.5-4.3) 3.9 (3.5-4.3) 4.1 (3.8-4.3) .08
Total bilirubin, mg/dL 0.5 (0.3-0.7) 0.5 (0.3-0.7) 0.5 (0.3-0.7) .80
SGOT, mg/dL 21.0 (17.0-27.0) 21.0 (17.0-27.0) 20.5 (18.0-26.0) .69
Alkaline phosphatase, IU/L. 80.0 (65.0-100.0) 80.0 (66.0-100.0) 79.5 (60.0-103.0) .54
WBC, 106/mL 7.5 (6.2-9.2) 7.5 (6.2-9.1) 7.5 (6.6-9.7) .25
Hematocrit, % 39.3 (35.7-42.0) 39.2 (35.5-42.0) 39.4 (36.0-41.6) .58
Platelets, 109/L 231.0 (186.0-286.0) 230.0 (183.0-284.0) 239.0 (200.0-295.0) .24
PTT 29.0 (26.5-32.3) 29.0 (26.5-32.3) 28.1 (26.3-32.0) .47
INR 1.0 (1.0-1.1) 1.0 (1.0-1.1) 1.0 (0.9-1.1) .94
Outcomes
Length of stay, days 2.0 (1.0-6.0) 2.0 (1.0-6.0) 2.0 (1.0-4.0) .41
CVA 26 (3.3) 22 (3.1) 4 (4.6) .52
Death 23 (2.9) 20 (2.9) 3 (3.5) .73
CVA/death 42 (5.3) 36 (5.1) 6 (6.9) .45
ASA, American Society of Anesthesiologists physical status classiﬁcation system; BUN, blood urea nitrogen; CAD, coronary artery disease; CEA, carotid
endarterectomy; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; INR, international normalized
ratio; PTT, partial thromboplastin time; SGOT, serum glutamic oxaloacetic transaminase; WBC, white blood cells.
aContinuous data are reported as median (interquartile range) and categoric data as number (%).
bP < .05.
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Patency end points could not be assessed.
Our analyses may have been underpowered and should
be interpreted in the context of a small sample size, espe-
cially in the TEVAR cohort, in which 36 CSBs and 52
SCTs were performed. In the overall cohort, we obtained
an OR of 0.42, with 84% power to detect a difference. In
the TEVAR cohort, at the OR of 0.15 that was obtained,
there was 92% power to detect a difference. However, in
the non-TEVAR cohort, we had only 7% power to detect
a difference at the OR of 0.93 that was obtained. The rela-
tively small sample sizes raise the potential for type II statis-
tical error. In addition, confounding by indication cannotbe excluded, meaning that patients chosen for either
surgical approach might have been more likely to have
traits that predisposed them to CVA/D. We chose inclu-
sive criteria for inclusion in each multivariable model
(P < .50 for entry into the model and P < .30 to remain
in the model) to account for possible confounders. Regard-
less, the research strategy used directly demonstrates the
power of a large, high-quality data set, such as NSQIP,
to gain insights into low frequency surgical procedures.
CONCLUSIONS
Despite improvements in surgical, anesthetic, and crit-
ical care technology, open cervical reconstruction of the
Table VII. Multivariable stepwise selection model for
cerebrovascular accident/death (CVA/D) in the non-
thoracic endovascular aortic repair (TEVAR) cohort
Factor Adjusted OR (95% CI) P
SCT (vs CSB)a 0.94 (0.15-5.86) .95
Age (per 10 years) 2.32 (1.29-4.17) <.01b
Current smoker 3.58 (1.07-11.96) .04b
Nonindependent status 7.34 (2.10-25.71) <.01b
Pre-op lab values (per 1 unit)
Sodium 1.22 (1.00-1.49) .05
White blood cells 1.22 (1.01-1.48) .04b
CI, Conﬁdence interval; CSB, carotid-subclavian bypass; OR, odds ratio;
SCT, subclavian-carotid transposition.
aSurgical approach (CSB vs SCT) was forced into the model as the variable
of interest.
bP < .05.
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combined CVA/D rate >5% in this contemporary work.
With TEVAR, this rate is as high as 10.2%. Choice of
cervical reconstruction technique was not associated with
the composite end point after adjustment for other factors.
The persistence of CVA/D postoperative complications in
contemporary CSB and SCT patients challenges all to
continue pursuit of evidence in this arena to guide thera-
peutic approaches.
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Supplementary Fig 1 (online only). Thoracic endovascular aortic repair (TEVAR) cohort: carotid-subclavian bypass
(CSB) surgical approach over time. Frequencies displayed adjacent to columns.
Supplementary Fig 2 (online only). Non-thoracic endovascular aortic repair (TEVAR) cohort: carotid–subclavian
bypass (CSB) surgical approach over time. Frequencies displayed adjacent to columns.
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Supplementary Table (online only). Current Procedure Terminology codesa
Carotidesubclavian bypass (CSB)
35606 CSB graft, w/ vein; carotid-subclavian
35506 CSB graft, w/ other than vein; carotid-subclavian
33891 CSB graft, with other than vein, transcervical retropharyngeal carotid-carotid, performed in conjunction
with endovascular repair of descending thoracic aorta, by neck incision
Subclavianecarotid transposition (SCT)
35694 SCT and/or reimplantation; subclavian to carotid artery
33889 Open subclavian to carotid artery transposition performed in conjunction with endovascular repair of descending
thoracic aorta, by neck incision, unilateral
Thoracic endovascular aortic repair (TEVAR)
33880 Endovascular repair of descending thoracic aorta (eg, aneurysm, pseudoaneurysm, dissection, penetrating
ulcer, intramural hematoma, or traumatic disruption); involving coverage of left subclavian artery origin,
initial endoprosthesis plus descending thoracic aortic extension(s), if required, to level of celiac artery origin.
(For radiological supervision and interpretation, use 75956 in conjunction with 33880.)
33881 Endovascular repair of descending thoracic aorta (eg, aneurysm, pseudoaneurysm, dissection, penetrating ulcer,
intramural hematoma, or traumatic disruption); not involving coverage of left subclavian artery origin, initial
endoprosthesis plus descending thoracic aortic extension(s), if required, to level of celiac artery origin.
(For radiological supervision and interpretation, use 75957 in conjunction with 33881.)
33883 Placement of proximal extension prosthesis for endovascular repair of descending thoracic aorta
(eg, aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma, or traumatic disruption);
initial extension
33884 Placement of proximal extension prosthesis for endovascular repair of descending thoracic aorta (eg, aneurysm,
pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma, or traumatic disruption); each additional
proximal extension (List separately in addition to code for primary procedure.)
33891 CSB graft, with other than vein, transcervical retropharyngeal carotid-carotid, performed in conjunction with
endovascular repair of descending thoracic aorta, by neck incision
33889 Open subclavian to carotid artery transposition performed in conjunction with endovascular repair of descending
thoracic aorta, by neck incision, unilateral
Carotid endarterectomy (CEA)
35301 Thromboendarterectomy, w/ or w/o patch graft; carotid, vertebral, subclavian, by neck incision
35390 Reoperation, carotid, thromboendarterectomy, more than one month after original operation
aAmerican Medical Association, Chicago, Ill.
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